CR20200133A - Formulaciones tópicas de cloroprocaína y métodos para utilizar las msimas - Google Patents
Formulaciones tópicas de cloroprocaína y métodos para utilizar las msimasInfo
- Publication number
- CR20200133A CR20200133A CR20200133A CR20200133A CR20200133A CR 20200133 A CR20200133 A CR 20200133A CR 20200133 A CR20200133 A CR 20200133A CR 20200133 A CR20200133 A CR 20200133A CR 20200133 A CR20200133 A CR 20200133A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formulations
- chloroprocaine
- methods
- topical
- mimas
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002023 chloroprocaine Drugs 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 241001044053 Mimas Species 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 238000005299 abrasion Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559220P | 2017-09-15 | 2017-09-15 | |
| PCT/IB2018/057073 WO2019053657A1 (en) | 2017-09-15 | 2018-09-14 | TOPICAL FORMULATIONS OF CHLOROPROCAINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200133A true CR20200133A (es) | 2020-05-09 |
Family
ID=63713967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200133A CR20200133A (es) | 2017-09-15 | 2018-09-14 | Formulaciones tópicas de cloroprocaína y métodos para utilizar las msimas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10792271B2 (https=) |
| EP (1) | EP3681473A1 (https=) |
| JP (1) | JP2020533321A (https=) |
| KR (1) | KR102759903B1 (https=) |
| CN (1) | CN111163756B (https=) |
| AU (1) | AU2018332212B2 (https=) |
| CA (1) | CA3070336C (https=) |
| CL (1) | CL2020000665A1 (https=) |
| CO (1) | CO2020002985A2 (https=) |
| CR (1) | CR20200133A (https=) |
| CU (1) | CU20200019A7 (https=) |
| EA (1) | EA202090735A1 (https=) |
| EC (1) | ECSP20022313A (https=) |
| IL (1) | IL273213B2 (https=) |
| JO (1) | JOP20200010A1 (https=) |
| MA (1) | MA50241A (https=) |
| MX (1) | MX2020002898A (https=) |
| PE (1) | PE20201281A1 (https=) |
| PH (1) | PH12020550029A1 (https=) |
| SG (1) | SG11202000992RA (https=) |
| WO (1) | WO2019053657A1 (https=) |
| ZA (1) | ZA202000601B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202139993A (zh) * | 2020-03-16 | 2021-11-01 | 瑞士商辛鐵堤卡公司 | 具有經改良之功能性的眼用氯普魯卡因(chloroprocaine)凝膠 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930000050B1 (ko) * | 1990-08-29 | 1993-01-06 | 브리스톨-마이어즈 스퀴브 컴페니 | 항균제 겔 배합물 |
| US6218428B1 (en) * | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| JP2004123634A (ja) * | 2002-10-03 | 2004-04-22 | Lion Corp | 眼科用組成物 |
| WO2004058329A2 (en) * | 2002-12-20 | 2004-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Ester combination local anesthetic |
| US20050137177A1 (en) | 2003-12-18 | 2005-06-23 | Shafer Steven L. | Ester combination local anesthetic |
| EA200701131A1 (ru) * | 2004-11-24 | 2007-12-28 | Алгоркс Фармасьютикалз, Инк. | Гелеобразная препаративная форма капсаициноида и способы её применения |
| ITMI20051633A1 (it) | 2005-09-06 | 2007-03-07 | Sint Sa | Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione |
| ITMI20122120A1 (it) * | 2012-12-12 | 2014-06-13 | Sint Sa | Composizione farmaceutica a base di cloroprocaina per la somministrazione intratecale ripetuta |
| CN103405576B (zh) * | 2013-08-23 | 2016-03-30 | 何学忠 | 一种治疗由焊接强光辐射引起的眼部疾病的滴眼液 |
-
2018
- 2018-09-14 MX MX2020002898A patent/MX2020002898A/es unknown
- 2018-09-14 JP JP2020513886A patent/JP2020533321A/ja active Pending
- 2018-09-14 KR KR1020207004474A patent/KR102759903B1/ko active Active
- 2018-09-14 AU AU2018332212A patent/AU2018332212B2/en active Active
- 2018-09-14 SG SG11202000992RA patent/SG11202000992RA/en unknown
- 2018-09-14 CU CU2020000019A patent/CU20200019A7/es unknown
- 2018-09-14 EP EP18779804.6A patent/EP3681473A1/en active Pending
- 2018-09-14 PE PE2020000669A patent/PE20201281A1/es unknown
- 2018-09-14 CN CN201880057219.1A patent/CN111163756B/zh active Active
- 2018-09-14 US US16/131,174 patent/US10792271B2/en active Active
- 2018-09-14 MA MA050241A patent/MA50241A/fr unknown
- 2018-09-14 CR CR20200133A patent/CR20200133A/es unknown
- 2018-09-14 WO PCT/IB2018/057073 patent/WO2019053657A1/en not_active Ceased
- 2018-09-14 EA EA202090735A patent/EA202090735A1/ru unknown
- 2018-09-14 IL IL273213A patent/IL273213B2/en unknown
- 2018-09-14 CA CA3070336A patent/CA3070336C/en active Active
-
2020
- 2020-01-17 PH PH12020550029A patent/PH12020550029A1/en unknown
- 2020-01-22 JO JOP/2020/0010A patent/JOP20200010A1/ar unknown
- 2020-01-29 ZA ZA2020/00601A patent/ZA202000601B/en unknown
- 2020-03-13 CL CL2020000665A patent/CL2020000665A1/es unknown
- 2020-03-13 CO CONC2020/0002985A patent/CO2020002985A2/es unknown
- 2020-04-15 EC ECSENADI202022313A patent/ECSP20022313A/es unknown
- 2020-09-01 US US17/008,913 patent/US11969403B2/en active Active
-
2024
- 2024-01-08 US US18/406,539 patent/US20240216323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3681473A1 (en) | 2020-07-22 |
| JP2020533321A (ja) | 2020-11-19 |
| IL273213B2 (en) | 2025-06-01 |
| IL273213B1 (en) | 2025-02-01 |
| KR20200053476A (ko) | 2020-05-18 |
| AU2018332212A1 (en) | 2020-02-27 |
| MX2020002898A (es) | 2020-11-06 |
| CA3070336C (en) | 2022-08-23 |
| CU20200019A7 (es) | 2020-11-30 |
| WO2019053657A1 (en) | 2019-03-21 |
| IL273213A (en) | 2020-04-30 |
| AU2018332212B2 (en) | 2023-03-16 |
| KR102759903B1 (ko) | 2025-01-23 |
| US11969403B2 (en) | 2024-04-30 |
| EA202090735A1 (ru) | 2020-06-22 |
| US20190083446A1 (en) | 2019-03-21 |
| US10792271B2 (en) | 2020-10-06 |
| BR112020003095A2 (pt) | 2020-08-25 |
| CL2020000665A1 (es) | 2020-09-21 |
| SG11202000992RA (en) | 2020-03-30 |
| JOP20200010A1 (ar) | 2020-01-22 |
| CA3070336A1 (en) | 2019-03-21 |
| CN111163756A (zh) | 2020-05-15 |
| ZA202000601B (en) | 2021-02-24 |
| PH12020550029A1 (en) | 2021-02-08 |
| CO2020002985A2 (es) | 2020-05-29 |
| ECSP20022313A (es) | 2020-07-31 |
| CN111163756B (zh) | 2022-04-15 |
| US20200390738A1 (en) | 2020-12-17 |
| US20240216323A1 (en) | 2024-07-04 |
| MA50241A (fr) | 2020-07-22 |
| PE20201281A1 (es) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CR20160130A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
| MX2016015636A (es) | Formulaciones cannabinoides estables. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
| MX2019001877A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
| ECSP21030482A (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| ECSP20022313A (es) | Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas | |
| DOP2015000175A (es) | Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular | |
| PY2018665A (es) | Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas | |
| UY38606A (es) | Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas | |
| CL2018002010A1 (es) | Derivados de indano y su uso en terapias. | |
| UY36958A (es) | Compuestos para administración intracelular |